|drug3448||Therapeutic Anticoagulation Wiki||1.00|
|drug717||Camostat Mesilate Wiki||0.38|
|D020141||Hemostatic Disorders NIH||0.27|
|D001778||Blood Coagulation Disorders NIH||0.27|
There is one clinical trial.
This study will evaluate the efficacy of oral Foipan® (camostat mesilate) compared with the current standard of care in reducing the duration of viral shedding of SARS-CoV-2 virus in patients with mild COVID-19 disease. Patients will attend up to 6 study visits over a period of up to 28 days.
Description: This outcome is defined as the time in days from randomization to the first of two consecutive negative test results.Measure: Time until cessation of shedding of SARS-CoV-2 virus Time: Up to 28 days
Description: Viral load from oropharyngeal swabs will be assessed as the level of nucleic acid over time.Measure: Sars-CoV-2 viral load (Nucleic Acid) Time: Up to 28 days
Description: Number of symptomatic patients with clinical worsening, defined as the development of respiratory distress or symptoms that require hospitalization,Measure: Clinical worsening of COVID-19 disease in symptomatic patients Time: Up to 28 days
Description: Number of patients that develop antibodies to SARS-CoV-2.Measure: Development of antibodies to SARS-CoV-2 Time: Up to 28 days
Description: This outcome is defined as absence of symptoms for at least 24 hours.Measure: Time until cessation of symptoms Time: Up to 28 days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports